Form 4 for OGN Organon & Co.
Accepted 2026-04-02 16:09:44 ET · period of report 2026-03-31 · accession 0001628280-26-023146 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-04-02 16:09 | 2026-03-31 | OGN | Weaver Kirke | Gen. Counsel, Corp. Secy | M - OptEx | $0.00 | +18.5K | 96.1K | +24% | $0 |
| DM | 2026-04-02 16:09 | 2026-03-31 | OGN | Weaver Kirke | Gen. Counsel, Corp. Secy | F - Tax | $5.70 | -5,275 | 92.6K | -5% | -$30.1K |
| D | 2026-04-02 16:09 | 2026-03-31 | OGN | Weaver Kirke | Gen. Counsel, Corp. Secy | A - Grant | $0.00 | +183.6K | 183.6K | New | $0 |
| DM | 2026-04-02 16:09 | 2026-03-31 | OGN | Weaver Kirke | Gen. Counsel, Corp. Secy | M - OptEx | $0.00 | -18.5K | 24.6K | -43% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-31 | M | A | 6,201 | $0.00 | 85,602.16 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-31 | F | D | 1,767 | $5.70 | 83,835.16 | D | — | — | (F1) The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. |
| 3 | Common | Common Stock | 2026-03-31 | M | A | 12,312 | $0.00 | 96,147.16 | D | — | — | |
| 4 | Common | Common Stock | 2026-03-31 | F | D | 3,508 | $5.70 | 92,639.16 | D | — | — | (F1) The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. |
| 5 | Derivative | Restricted Stock Units | 2026-03-31 | A | A | 183,639 | $0.00 | 183,639 | D | — · — to — | 183,639 Common Stock | (F2) On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F2) On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. (F2) On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. |
| 6 | Derivative | Restricted Stock Units | 2026-03-31 | M | D | 6,201 | $0.00 | 0 | D | — · — to — | 6,201 Common Stock | (F3) Each RSU represents a contingent right to receive one share of Organon common stock. (F4) On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. (F4) On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. |
| 7 | Derivative | Restricted Stock Units | 2026-03-31 | M | D | 12,312 | $0.00 | 24,625 | D | — · — to — | 12,312 Common Stock | (F3) Each RSU represents a contingent right to receive one share of Organon common stock. (F5) On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. (F5) On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. |